HKSE:2269

WuXi Biologics (Cayman) Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:44 UTC

Last close

n/aHKD

Market data

34.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
12.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
22.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
12.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.25 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

2,203

2016-12-31 to 2025-12-31100 at the start2,203

Sales: 100.00 on 2016-12-31 to 2203.17 on 2025-12-31, up 2103%.

Profit

3,479

2016-12-31 to 2025-12-31100 at the start3,479

Profit: 100.00 on 2016-12-31 to 3478.73 on 2025-12-31, up 3379%.

Shares in issue

123

2016-12-31 to 2025-12-31100 at the start123

Shares in issue: 100.00 on 2016-12-31 to 122.73 on 2025-12-31, up 23%.

Sales is at 2203, Profit is at 3479, Shares in issue is at 123, against 100 in 2016.

Sales is at 2203, Profit is at 3479, Shares in issue is at 123, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 1002,203
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit, where the first year is 1003,479
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Shares in issue, where the first year is 100123
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY